Who
John B. Harlow Jr.
President and COO
Company insider
Files Form 4 as: President and COO, Larimar Therapeutics; Chief Commercial Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Dec 2025
- Last trade
- 29 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 1 Oct 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 29 Sep 2026filed 1 Oct 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —424,536 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —424,536 | filing |
| 4 Dec 2025filed 8 Dec 2025 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —380,000 at $0.00 | filing |
| 4 Dec 2025filed 8 Dec 2025 | Esperion Therapeutics | SEC FORM 4 Code A | —424,536 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.